Table 2.
Viability of melanoma lymph node metastases and PDXs analyzed ex vivo after treatment with Vemurafenib (2 μM)
| Patient No. | Mutation | Relative viability (% of control)1 |
||||
|---|---|---|---|---|---|---|
| Lymph node | PDX passage2,3 |
|||||
| Lowest | Highest | |||||
| Melmet-334 | BRAF | n.a.* | 52 | (4) | - | (n.a.)** |
| Melmet-347 | BRAF | 31 | 64 | (1) | 13 | (3) |
| Melmet-350 | BRAF | 59 | - | (0) | - | (1) |
| Melmet-351 | BRAF | n.a. | 57 | (2) | 56 | (6) |
| Melmet-356 | BRAF | 102 | - | (0) | - | (4) |
| Melmet-363 | BRAF | 52 | 43 | (7) | 28 | (8) |
| Melmet-376 | BRAF | 52 | 33 | (2) | 43 | (6) |
| Melmet-380 | BRAF | 16 | 26 | (0) | 42 | (3) |
| Melmet-381 | BRAF | 30 | 87 | (4) | 11 | (7) |
| Melmet-382 | BRAF | 35 | 17 | (2) | 18 | (5) |
| Melmet-389 | BRAF | n.a. | 61 | (0) | 12 | (6) |
| Melmet-393 | BRAF | n.a. | 30 | (3) | 20 | (6) |
| Melmet-358 | NRAS | 132 | 86 | (0) | 107 | (5) |
| Melmet-365 | NRAS | 201 | 122 | (1) | 116 | (5) |
| Melmet-367 | NRAS | 91 | 118 | (7) | n.a. | (n.a.) |
| Melmet-369 | NRAS | 74 | 169 | (0) | 271 | (3) |
| Melmet-388 | NRAS | 89 | 67 | (0) | 125 | (7) |
| Melmet-256 | Wt/Wt | 83 | 86 | (0) | 80 | (7) |
| Melmet-370 | Wt/Wt | 70 | 98 | (1) | 103 | (10) |
| Melmet-374 | Wt/Wt | n.a. | 79 | (3) | 103 | (5) |
| Melmet-404 | Wt/Wt | 116 | 77 | (0) | 103 | (1) |
1 Percentage survival.
2 Number of passages in parentheses.
3 PDX for Melmet-350, -356 not analyzed due to control sample not growing.
* n.a. = Not analyzed due to limited tumor material available.
** Only one PDX passage analyzed.